[Retracted] Clinical Application of Anlotinib Combined with Docetaxel: Safe and Effective Treatment for Lung Carcinoma

Table 3

Comparison of adverse reactions between the two groups (%).

Group	Number of patients	Anemia	Pyrexia	Proteinuria	Nausea and vomiting	Abnormal liver and kidney function	Overall incidence
Control group	42	3 (7.14)	5 (11.90)	6 (9.52)	9 (21.43)	4 (9.52)	27 (64.29)
Experimental group	42	2 (4.76)	3 (7.14)	1 (2.38)	5 (11.90)	1 (2.38)	12 (28.57)
	—	10769
	—	0.001